Submassive Pulmonary Embolism Experience With EKOS (SPEEK)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lisa K Stevens, MSN
- Phone Number: 7406894426
- Email: lisas@fmchealth.org
Study Contact Backup
- Name: Krishna Mannava, MD
- Phone Number: 740-687-6910
- Email: drkmannava@fmchealth.org
Study Locations
-
-
Ohio
-
Lancaster, Ohio, United States, 43130
- Recruiting
- Fairfield Medical Center
-
Contact:
- Lisa K Stevens, MSN
- Phone Number: 740-689-4426
- Email: lisas@fmchealth.org
-
Contact:
- Krishna Mannava, MD
- Phone Number: 7406876910
- Email: kmannava@fmchealth.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Acute symptomatic PE confirmed by CT, with filling defect in at least one main or segmental pulmonary artery.
- RV dysfunction as evidenced by RV/LV ratio > 0.9 on echo
- Ability to give informed consent or Legally Authorized Representative (LAR) is able to give consent
- PE symptom duration < 21 days
- Age >18 years
- And, a MBS baseline measurement above 3 plus at least one of the following: O2 sat < 90% RA, or inability to maintain a HR <100, or inability to maintain a Systolic Bp > 100. Whichever measurement is chosen for inclusion criteria in addition to the MBS will also be used in determination of therapeutic endpoint (i.e. O2 Sat., HR<100 or BP >100)..
Exclusion Criteria:
- Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year
- Recent (within one month) or active bleeding from a major organ
- Hemoglobin (Hgb) < 8.0
- Platelets < 60 thousand/µL
- Major surgery within seven days
- Clinician deems high-risk for catastrophic bleeding
- History of heparin-induced thrombocytopenia (HIT)
- Pregnancy
- Catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment
- Systolic blood pressure less than 80 mm Hg despite vasopressor or inotropic support
- Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR)
- Evidence of irreversible neurological compromise
- Life expectancy < 30 days
- Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of RV dysfunction
Time Frame: 48 hours post catheter removal
|
Reduction of RV dysfunction as evidenced by a reduction in RVSP and or a reduction in RV/LV ratio measured by echo at baseline and again at 48 ±6 hours post EKOS catheter removal
|
48 hours post catheter removal
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Lisa K Stevens, MSN, Fairfield Medical Center
- Principal Investigator: Krishna Mannava, MD, Fairfield Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FMCspeekEKOSstudy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.